Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and
effective for the treatment of renal cell cancer when other treatments have failed.